TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11095577

Group type: EXPERIMENTAL
Intervention: Ro 41‐3290 (5, 10, and 30 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9071224

Group type: EXPERIMENTAL
Intervention: Lens fluorometry
Number of subjects: 79

Group type: COMPARATOR
Intervention: Age alone
Number of subjects: 79
Study: 8020525

Group type: EXPERIMENTAL
Intervention: iomeprol-350 (350 mgI/ml)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: iomeprol-400 (400 mgI/ml)
Number of subjects: 120

Group type: COMPARATOR
Intervention: iopamidol-370 (370 mgI/ml)
Number of subjects: 120
Study: 2690305

Group type: EXPERIMENTAL
Intervention: Oxytocin + early artificial rupture of the membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal gel (first dose: 1 mg, second dose 1 or 2 mg, six hours later)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prostaglandin E2 vaginal gel
Number of subjects: 0
Study: 1135409

Group type: EXPERIMENTAL
Intervention: Atmospheric oxygen breathing during radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no atmospheric oxygen breathing)
Number of subjects: 0
Study: 31015098

Group type: EXPERIMENTAL
Intervention: MA + SSRIs
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: EA + SSRIs
Number of subjects: 477
Study: 29056453

Group type: EXPERIMENTAL
Intervention: Closed-loop (CL) auditory training for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory working-memory (WM) task
Number of subjects: 0
Study: 25168164

Group type: EXPERIMENTAL
Intervention: Stepwise addition (SWA) of bolus insulin aspart
Number of subjects: 77000

Group type: COMPARATOR
Intervention: Full basal-bolus (FBB) therapy
Number of subjects: 77000
Study: 22313171

Group type: EXPERIMENTAL
Intervention: Isoflavones and berberine (ISB)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Calcium and vitamin D(3) (CaD)
Number of subjects: 120
Study: 20478551

Group type: EXPERIMENTAL
Intervention: Intramuscular glucocorticoid injection
Number of subjects: 32

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 32
Study: 18400058

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 1177

Group type: COMPARATOR
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 1177
Study: 15977084

Group type: EXPERIMENTAL
Intervention: Percutaneous transcatheter closure of PFO
Number of subjects: 24

Group type: COMPARATOR
Intervention: Antimigraine drugs
Number of subjects: 24
Study: 12464139

Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 11
Study: 10480508

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of waist circumference
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Waist circumference in diabetic group
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 194
Study: 7702137

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Blind oral intubation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 35
Study: 2746493

Group type: EXPERIMENTAL
Intervention: Low dose lorazepam (0.0225 mg/kg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High dose lorazepam (0.045 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Diazepam (0.15 mg/kg)
Number of subjects: 6
Study: 901139

Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30957443

Group type: EXPERIMENTAL
Intervention: Huoxue Sanfeng acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Xingnao Kaiqiao acupuncture + nifedipine
Number of subjects: 70
Study: 28816735

Group type: EXPERIMENTAL
Intervention: Short, frequent breaks (SBs)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Longer, planned breaks (LBs)
Number of subjects: 49
Study: 26003804

Group type: EXPERIMENTAL
Intervention: Adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) followed by routine adjuvant systemic chemotherapy
Number of subjects: 176

Group type: COMPARATOR
Intervention: Systemic chemotherapy only
Number of subjects: 176
Study: 23172931

Group type: COMPARATOR
Intervention: AM dose (once-daily antihypertensive medications taken in the morning)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: PM dose (once-daily antihypertensives taken at bedtime)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Add-on dose (once-daily antihypertensives taken in the morning and an additional antihypertensive medication before bedtime)
Number of subjects: 147
Study: 21816199

Group type: EXPERIMENTAL
Intervention: 15 μg VLP vaccine
Number of subjects: 4563

Group type: EXPERIMENTAL
Intervention: 45 μg VLP vaccine
Number of subjects: 4563

Group type: EXPERIMENTAL
Intervention: 5 μg VLP vaccine
Number of subjects: 4563

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 4563
Study: 19366957

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 18
Study: 16690579

Group type: EXPERIMENTAL
Intervention: Self-report of daily living skills using the Health Assessment Questionnaire (HAQ)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Performance-based test using the Assessment of Motor and Process Skills (AMPS)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive status in participants with SLE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Disease severity in participants with SLE
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HAQ scores
Number of subjects: 30
Study: 15454063

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 1192
Study: 11550740

Group type: EXPERIMENTAL
Intervention: Problem-solving therapy (PST)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Behavioral treatment (BT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Relapse prevention training (RPT)
Number of subjects: 80
Study: 9024439

Group type: EXPERIMENTAL
Intervention: Training for intervention clinic staff based on National Asthma Education and Prevention Program guidelines
Number of subjects: 22
Study: 8102918

Group type: EXPERIMENTAL
Intervention: salmeterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: salbutamol
Number of subjects: 20
Study: 2868074

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Doxorubicin plus cyclophosphamide (AC)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus Doxorubicin and Cyclophosphamide (TAM plus AC)
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: TAM followed by AC
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: AC followed by TAM
Number of subjects: 339

Group type: COMPARATOR
Intervention: All three arms (TAM, AC, TAM plus AC)
Number of subjects: 339
Study: 31350111

Group type: EXPERIMENTAL
Intervention: Speakers with PD
Number of subjects: 44

Group type: COMPARATOR
Intervention: HOA speakers
Number of subjects: 44
Study: 30074671

Group type: EXPERIMENTAL
Intervention: Baby-led weaning (BLW)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Traditional spoon feeding (TSF)
Number of subjects: 280
Study: 27908191

Group type: COMPARATOR
Intervention: Display window width of 100 HU
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Display window width of 40 HU
Number of subjects: 6
Study: 25519029

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) administration
Number of subjects: 2
Study: 22440535

Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements and telemedical monitoring with daily assessment of body weight, number of taken oral energy supplements and state of health
Number of subjects: 26

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 26
Study: 20025554

Group type: EXPERIMENTAL
Intervention: Mitiglinide (initial dose 7.5 - 15 mg titrated to 30 mg daily) + voglibose (0.9 mg daily)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Voglibose (0.9 mg daily)
Number of subjects: 36
Study: 18217904

Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 98

Group type: COMPARATOR
Intervention: rATG
Number of subjects: 98
Study: 15946554

Group type: EXPERIMENTAL
Intervention: Hepatectomy and postoperative therapy using lamivudine plus thymosin alpha1
Number of subjects: 33

Group type: COMPARATOR
Intervention: Hepatectomy only
Number of subjects: 33
Study: 12742477

Group type: EXPERIMENTAL
Intervention: Sirolimus with low-dose Prograf
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus in calcineurin-free protocols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sirolimus with full-dose Prograf
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 0
Study: 10388978

Group type: EXPERIMENTAL
Intervention: Intensive blood glucose control policy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Conventional blood glucose control policy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Tight BP control policy
Number of subjects: 2

Group type: COMPARATOR
Intervention: Less tight BP control policy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients with macrovascular complications
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Patients with microvascular complications
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Insulin-treated patients with two or more hypoglycemic episodes
Number of subjects: 2
Study: 8840366

Group type: EXPERIMENTAL
Intervention: Interferon (IFN)‐α treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 1796238

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg/kg body weight once daily for 5 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quinine 10 mg/kg body weight once daily for 3 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quinine (both regimens)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Quinine (single daily doses)
Number of subjects: 31
Study: 6404290

Group type: EXPERIMENTAL
Intervention: Ro 15-1788 200 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Diazepam 20 mg
Number of subjects: 6
Study: 31675943

Group type: EXPERIMENTAL
Intervention: Integrated nutrition intervention including food vouchers, egg-based nutritious snacks, micronutrient powder, child feeding counselling, WASH, behaviour change communication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine health messages provided by the government
Number of subjects: 0
Study: 30080284

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) plus mycophenolate mofetil (MMF)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) plus mycophenolate mofetil (MMF)
Number of subjects: 117
Study: 27569229

Group type: EXPERIMENTAL
Intervention: Lateral position group (Group L, n = 34)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Supine position group (Group S, n = 38)
Number of subjects: 72
Study: 24530169

Group type: EXPERIMENTAL
Intervention: Yoga plus usual GP care
Number of subjects: 133
Study: 22526914

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Supportive Counseling (SC)
Number of subjects: 68
Study: 19127264

Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) diagnosis of malignancy
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) detection of malignant lesions
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: General Practitioner (GP) detection of individuals affected with malignancy
Number of subjects: 491
Study: 17559458

Group type: EXPERIMENTAL
Intervention: Intraligamental lignocaine (2% lignocaine solution with adrenaline 1 : 80 000)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group (no lignocaine)
Number of subjects: 86
Study: 15507811

Group type: EXPERIMENTAL
Intervention: Chiropractic or physiotherapy treatment
Number of subjects: 314
Study: 11803613

Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) > or = 30 (Group I)
Number of subjects: 427

Group type: COMPARATOR
Intervention: Body Mass Index (BMI) < 30 (Group II)
Number of subjects: 427
Study: 9632126

Group type: EXPERIMENTAL
Intervention: 15 mmol Mg daily for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo daily for 3 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Increased plasma Mg concentration
Number of subjects: 50
Study: 7870633

Group type: EXPERIMENTAL
Intervention: Withdrawal of anti-hypertensive therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Continuation of anti-hypertensive therapy
Number of subjects: 60
Study: 2846455

Group type: EXPERIMENTAL
Intervention: Antiembolism stockings (AES)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dihydroergotamine (DHE)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 12
Study: 30514264

Group type: EXPERIMENTAL
Intervention: Empowerment self-defense (ESD) training, 12 hours over 6 weeks with refreshers
Number of subjects: 6644

Group type: EXPERIMENTAL
Intervention: Empowerment self-defense (ESD) training
Number of subjects: 6644

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 6644
Study: 27740565

Group type: EXPERIMENTAL
Intervention: High-Fidelity Simulation (HFS)
Number of subjects: 0
Study: 24759826

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 938

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 938

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) based ART
Number of subjects: 938

Group type: COMPARATOR
Intervention: Nevirapine-based ART
Number of subjects: 938
Study: 22691892

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg per day for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20216533

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy (oral amoxicillin 1500 mg/day, tetracycline 1500 mg/day, metronidazole 750 mg/day)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Antibiotic combination therapy
Number of subjects: 210
Study: 18845665

Group type: EXPERIMENTAL
Intervention: Routine T-stenting with sirolimus-eluting stents (SES) in both branches
Number of subjects: 202

Group type: COMPARATOR
Intervention: Provisional T-stenting with SES placement in the main branch followed by kissing-balloon angioplasty and provisional SES placement in the side branch
Number of subjects: 202
Study: 16085582

Group type: EXPERIMENTAL
Intervention: Doppler-based intracoronary Q measurement using a proprietary guidewire device during adenosine-induced hyperemic flow (140 mug/kg/min for 7 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APV-derived CFVR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doppler-based intracoronary Q measurement
Number of subjects: 0
Study: 12450711

Group type: EXPERIMENTAL
Intervention: Fluoride-containing dentifrice (Sensodyne Baking Soda)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Non-fluoride-containing dentifrice (Sensodyne Original)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (Filtek Z250/3M)
Number of subjects: 180
Study: 10358492

Group type: EXPERIMENTAL
Intervention: High likelihood of pain and difficult to console
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: High likelihood of pain and easily consoled
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low likelihood of pain and difficult to console
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Low likelihood of pain and easily consoled
Number of subjects: 48
Study: 7864267

Group type: EXPERIMENTAL
Intervention: Early-night sleep deprivation (3:00 a.m. to 7:00 a.m.) followed by recovery sleep (11:00 p.m. to 7:00 a.m.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Late-night sleep deprivation (9:00 p.m. to 1:00 a.m.) followed by recovery sleep
Number of subjects: 41

Group type: COMPARATOR
Intervention: Early-night sleep deprivation
Number of subjects: 41

Group type: COMPARATOR
Intervention: Late-night sleep deprivation
Number of subjects: 41
Study: 2285584

Group type: EXPERIMENTAL
Intervention: 50 microgram ethinylestradiol (EE2)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 165
Study: 7029758

Group type: EXPERIMENTAL
Intervention: Z-plasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Incision and drainage or marsupialization (Control)
Number of subjects: 0
Study: 31884320

Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 173
Study: 31488119

Group type: COMPARATOR
Intervention: Medical debriefing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TeamGAINS debriefing
Number of subjects: 0
Study: 28926095

Group type: EXPERIMENTAL
Intervention: Rivaroxaban treatment
Number of subjects: 7145

Group type: COMPARATOR
Intervention: Hypothetical test product (20% change in AUC)
Number of subjects: 7145
Study: 25855325

Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH) 75 IU
Number of subjects: 219

Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg
Number of subjects: 219
Study: 23296694

Group type: EXPERIMENTAL
Intervention: Benznidazole 5 mg/kg in two daily doses for 60 days (Group A)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Benznidazole 7.5 mg/kg in a single daily dose for 30 days (Group B)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Both regimens of benznidazole
Number of subjects: 124
Study: 21362162

Group type: EXPERIMENTAL
Intervention: Ferroquine (400 to 1,600 mg single dose; up to 800 mg repeated dose)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 19906346

Group type: EXPERIMENTAL
Intervention: Olanzapine/fluoxetine combination (OFC)
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 788

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 788
Study: 16475604

Group type: EXPERIMENTAL
Intervention: Fluoridated dentifrice (Sensodyne Original Formula) with restorative materials
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Non-fluoridated dentifrice (Sensodyne Sodium Bicarbonate) with restorative materials
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Ketac‐Fil with fluoridated dentifrice
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Conventional glass ionomer cement with dentifrices
Number of subjects: 240
Study: 12087932

Group type: EXPERIMENTAL
Intervention: Educational program (EP)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Regular verbal counselling (VC)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Patch subgroup (EP)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Patch subgroup (VC)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Gel subgroup (EP)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Gel subgroup (VC)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Continuous HRT regimen (VC)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Sequential HRT regimen (VC)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Continuous HRT regimen (EP)
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: Sequential HRT regimen (EP)
Number of subjects: 1192
Study: 10566550

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol supplementation
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Beta-carotene supplementation
Number of subjects: 652

Group type: COMPARATOR
Intervention: GSTM1 null genotype
Number of subjects: 652
Study: 8722977

Group type: EXPERIMENTAL
Intervention: Warmed local anesthetic (40 degrees C)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Room temperature local anesthetic (21 degrees C)
Number of subjects: 26
Study: 2014947

Group type: EXPERIMENTAL
Intervention: Propranolol plus Is‐5‐Mn (40 mg twice a day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propranolol plus Is‐5‐Mn
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Propranolol and Propranolol plus Is‐5‐Mn
Number of subjects: 50
Study: 6185788

Group type: EXPERIMENTAL
Intervention: Medroxalol (100-400 mg twice daily)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Medroxalol + Hydrochlorothiazide (12.5 mg twice daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (after medroxalol withdrawal)
Number of subjects: 29
Study: 30907001

Group type: COMPARATOR
Intervention: 23‐valent pneumococcal polysaccharide vaccine (23vPPV)
Number of subjects: 4725

Group type: COMPARATOR
Intervention: Facebook advertising and snowball sampling
Number of subjects: 4725
Study: 28107276

Group type: EXPERIMENTAL
Intervention: Deep NMB (rocuronium bolus and infusion maintaining a posttetanic count of 1‐2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moderate NMB (rocuronium bolus and top‐ups maintaining a train‐of‐four count of 1‐2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Deep NMB
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moderate NMB
Number of subjects: 60
Study: 26253567

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25-50 mg
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Amiloride 10-20 mg
Number of subjects: 486

Group type: EXPERIMENTAL
Intervention: Combination of hydrochlorothiazide and amiloride at half doses
Number of subjects: 486

Group type: COMPARATOR
Intervention: Placebo (during single-blind run-in)
Number of subjects: 486
Study: 23599119

Group type: EXPERIMENTAL
Intervention: Probiotic B. infantis (4.2 × 10(9) colony‐forming units two times daily)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy control infants (N=6)
Number of subjects: 16
Study: 21306798

Group type: EXPERIMENTAL
Intervention: Snoezelen room
Number of subjects: 0

Group type: COMPARATOR
Intervention: Garden condition
Number of subjects: 0
Study: 19666658

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate powder
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sevelamer hydrochloride tablets
Number of subjects: 31
Study: 18051724

Group type: EXPERIMENTAL
Intervention: Upsher‐scope (USSP)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Macintosh direct laryngoscope (MDLS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both USSP and MDLS
Number of subjects: 50
Study: 16052334

Group type: EXPERIMENTAL
Intervention: Magnetization transfer ratio (MTR) measurements in patients with TSC
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched)
Number of subjects: 4